Now there is an up-to-date guide for optimizing pharmacologictherapy in treating patients with heart failure. Reflecting currentpractice at leading medical centers, Heart Failure:Pharmacologic Management provides both the biologic andpathologic underpinnings of each pharmacologic agent in currentuse. It also supplies detailed discussions of the clinicalinvestigations that support current understanding of the risks andbenefits associated with the use of these drugs. Thoroughreferences make the book useful to the novice as well as theexperienced clinician.
Initial chapters focus on agents that are consideredstandard care:
* * diuretics
* ACE inhibitors
* angiotensin receptor antagonists
* aldosterone antagonists
* beta-blockers
The discussion moves to agents currently underinvestigation:
* * Vasopressin antagonists
* erythropoietin
Next, the authors consider some controversial drugs:
* * inotropic agents
* antiarrhythmic drugs
* anticoagulants
An insightful examination of pharmacogeneticsconsiders:
* * how studies of the genetic profile of patients helps determinewhich patient populations are most likely to respond to a givenclass of drugs
* the potential use of pharmacogenetics to tailor a pharmacologicregimen for maximum benefit and minimum risk
Multidrug pharmacy for heart failure therapy
An extremely helpful concluding chapter provides a roadmap ofdrugs with which to approach the patient with heart failure, alongwith an overview of the skills you need to use it most effectively.This straightforward, step-by-step algorithm will save youcountless hours of research and help you make your prescribingdecisions with confidence.
Arthur M. Feldman
Heart Failure Herzversagen / Herzinsuffizienz Medical Science Medizin